Thomas K. Equels, CEO & President at AIM ImmunoTech Inc. (AIM), bought 107 shares at $7.70 ($824) on 2025-06-13, disclosed to the SEC on 2025-06-16.
Open-market purchase of $824 AIM by CEO & President. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| AIM | BUY | 2026-09-16 | $5K | — | Filing → |
| AIM | BUY | 2026-09-15 | $1K | — | Filing → |
| AIM | BUY | 2025-06-13 | $896 | — | Filing → |